ML
CRBP icon

McAdam LLC’s Corbus Pharmaceuticals CRBP Stock Holding History

McAdam LLC’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-334
Closed -$6K – 264
2022
Q4 		$6K Hold
334
– – ﹤0.01% 194
2022
Q3 		$2K Hold
334
– – ﹤0.01% 217
2022
Q2 		$3K Hold
334
– – ﹤0.01% 220
2022
Q1 		$5K Hold
334
– – ﹤0.01% 213
2021
Q4 		$6K Hold
334
– – ﹤0.01% 194
2021
Q3 		$10K Hold
334
– – ﹤0.01% 179
2021
Q2 		$14K Buy
+334
New +$18.5K ﹤0.01% 176
2018
Q2 		– Sell
-3
Closed -$1K – 666
2018
Q1 		$1K Buy
+3
New +$674 ﹤0.01% 619

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

McAdam LLC's CRBP Position: Q1 2023 in Review

McAdam LLC sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 334 shares — an estimated $6K sold.

McAdam LLC first reported a position in CRBP in Q1 2018 and held it in 8 quarters. The position peaked at $14K in Q2 2021. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • McAdam LLC reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • McAdam LLC sold 334 Corbus Pharmaceuticals shares in Q1 2023, an estimated $6K.
  • McAdam LLC first reported a position in Corbus Pharmaceuticals in Q1 2018 and held it in 8 quarters.
  • McAdam LLC's Corbus Pharmaceuticals position peaked at $14K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on McAdam LLC's 13F filing for Q1 2023, filed 24 Apr 2023.